DANIEL DAMITIO: Open Payments
NPI 1982180386 · BILOXI, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$254 in 9 payments from 4 companies in 2025. Trend: 2023 $273 · 2024 $308 · 2025 $254
Food & beverage: $254
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. | 5 | $101 |
| GlaxoSmithKline, LLC. | 1 | $95 |
| AstraZeneca Pharmaceuticals LP | 2 | $35 |
| ABBVIE INC. | 1 | $23 |
Products named: AREXVY, VRAYLAR, BREZTRI, FARXIGA.
Industry payments across MS — which companies pay providers there.
